CHMP rejects authorisation for Alzheimer’s drug over side effects

Antiamyloids slow the progression of Alzheimer’s disease in the early stages.

To date, three drugs have demonstrated positive results and an impact on the ability to eliminate amyloid protein: aducanumab, lecanemab and donanemab. + read more

In Spain, 800,000 people suffer from Alzheimer’s disease, with 40,000 new cases added each year

From 19 to 22 September, Malaga will host the International Congress on Neurodegenerative Diseases, dedicated to World Alzheimer’s Day. + read more

Spain Not Ready for New Era of Alzheimer’s

Always on the run to detect the disease as quickly as possible. Alzheimer’s diseaseand to be able to combat it more effectively than so far, Spain must act together. Because while it is foreseeable that the country’s hospitals will have conventional plasma-based biomarkers this year, the advent of new drugs such as Lecanemab or Donanemab This could lead to overcrowding of medical facilities, as is happening today in the United States.

+ read more

Concern grows over decline in sales of nervous system drugs

There are growing concerns about the decline in sales of drugs for the nervous system. As a result of the decline in demand for drugs in areas such as neurology, only antiepileptic drugs show meager growth in euro terms. This is shown by data provided by the firm IQVIA, which suggests that accounting is stagnating after six years of moderate growth, especially noticeable in autumn 2022.

More than 120 molecules under study offer hope for fighting Alzheimer’s disease

According to Iqvia’s Future of R&D report, the vast majority of these are designed to alter the course of disease. + read more

Dementia patients need universal palliative care

The Spanish Society of Psychogeriatrics has developed the IV course on Multidisciplinary Care and Intervention in Dementia at the Madrid headquarters of the University Hospital of Navarra. + read more